822. Novel Rescue Therapy Options: Drugs, Dosing Strategies, Combination
Session: Symposium: SOS: The Rescue from Antibacterial Resistance?
Saturday, October 22, 2011: 8:45 AM
Room: 104ABC

Robert Moellering, Jr Jr., MD, FIDSA, Harvard Medical School, Boston, MA; Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Robert C. Moellering, Jr., M.D. is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School. He served as Physician-in-Chief at the New England Deaconess Hospital from 1981 until 1996. He subsequently served as the Herrman Ludwig Blumgart Professor of Medicine at Harvard Medical School (HMS) and Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts through 2005. In that position, he served as chairman of one of the major academic departments of medicine at Harvard Medical School. Trained as an infectious diseases specialist, Dr. Moellering has been actively involved in laboratory research for the past 40 years. His work includes numerous studies of the mechanism of action and mechanisms of resistance to antimicrobial agents. He has defined some of the important mechanisms of interaction of antimicrobial agents, particularly against the enterococcus which has been a particular investigative interest for many years. He was the first to define the clinical utility of penicillin/gentamicin therapy for enterococcal endocarditis and he and his laboratory colleagues have defined many of the important mechanisms of resistance to antimicrobial agents in this increasingly important organism. More recently he and his colleagues have been investigating the mechanisms of resistance to vancomycin, daptomycin and oxazolidinones in Staphylococcus aureus and are studying the basis for pathogenesis in enterococci and staphylococci. His work is reported in over 400 publications in scientific journals.
Dr. Moellering received his M.D. degree cum laude from Harvard Medical School and served as a medical intern and resident at the Massachusetts General Hospital where he was also a fellow in infectious diseases prior to joining the staff of the Massachusetts General Hospital and the faculty of HMS in 1970. He served as chairman of the Department of Medicine at the Deaconess Hospital from 1981 to 1996 and was the Shields Warren-Mallinckrodt Professor of Medical Research at HMS from 1981 to 1998 when he assumed the Herrman Blumgart Professorship of Medicine at HMS. In addition, he was president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, the faculty multispecialty practice group at BIDMC. Dr. Moellering received an honorary Doctor of Science degree from Valparaiso University in 1980 and is also the recipient of the Garrod Medal from the British Society for Antimicrobial Chemotherapy, the Feldman Award and the Maxwell Finland Award from the Infectious Diseases Society of America of which he served as President from 1990-1991, the Hoechst-Roussel Award from the American Academy of Microbiology, the Finland Award of the National Foundation for Infectious Diseases, and in 2006 the Maxwell Finland Award for Scientific Achievement from the National Foundation for Infectious Diseases. Most recently, he is the 2008 recipient of the Alexander Fleming Award for Lifetime Achievement from the Infectious Diseases Society of America. Dr. Moellering is a Fellow of the Infectious Diseases Society of America, the American Academy of Microbiology and the American College of Physicians, and has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. He is also an Honorary Fellow of the Royal College of Physicians and a Master of the American College of Physicians-American Society of Internal Medicine. He is Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America, Editor, Sanford Guide to Antimicrobial Therapy, and Associate Editor of the Journal of Infection and Public Health.

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.